Zobrazeno 1 - 10 of 16 pro vyhledávání: '"Keiichiro Okuda"'
1
Akademický článek
Enhanced Antitumor Effect in Liver Cancer by Amino Acid Depletion-Induced Oxidative Stress
Autor: Keiichiro Okuda, Atsushi Umemura, Seita Kataoka, Kota Yano, Aya Takahashi, Shinya Okishio, Hiroyoshi Taketani, Yuya Seko, Taichiro Nishikawa, Kanji Yamaguchi, Michihisa Moriguchi, Hayato Nakagawa, Yu Liu, Yasuhide Mitsumoto, Yoshihiro Kanbara, Toshihide Shima, Takeshi Okanoue, Yoshito Itoh
Publikováno v: Frontiers in Oncology, Vol 11 (2021)
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. HCC cells consume large amounts of glutamine to survive, but can adapt to glutamine depletion in the presence of an exogenous asparagine. L-asparaginase (ASNase) converts
Externí odkaz: https://doaj.org/article/51f700cc3d644c598a99a775e3d1e527
Zobrazit plný text záznamu
2
Akademický článek
Tyrosine Kinase Inhibitors Stimulate HLA Class I Expression by Augmenting the IFNγ/STAT1 Signaling in Hepatocellular Carcinoma Cells
Autor: Aya Takahashi, Atsushi Umemura, Kota Yano, Shinya Okishio, Seita Kataoka, Keiichiro Okuda, Yuya Seko, Kanji Yamaguchi, Michihisa Moriguchi, Takeshi Okanoue, Yoshito Itoh
Publikováno v: Frontiers in Oncology, Vol 11 (2021)
Combination treatment with tyrosine kinase inhibitors (TKIs) and immunotherapies has shown efficacy in the treatment of multiple cancers, but the immunomodulatory effect of TKIs on the tumor cell phenotype remains unknown in hepatocellular carcinoma
Externí odkaz: https://doaj.org/article/f4023ab948ff40a9a22932d21b98616e
Zobrazit plný text záznamu
3
Akademický článek
Potential Therapeutic Targets and Promising Agents for Combating NAFLD
Autor: Atsushi Umemura, Seita Kataoka, Keiichiro Okuda, Yuya Seko, Kanji Yamaguchi, Michihisa Moriguchi, Takeshi Okanoue, Yoshito Itoh
Publikováno v: Biomedicines, Vol 10, Iss 4, p 901 (2022)
Nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH), is a growing cause of liver cirrhosis and liver cancer worldwide because of the global increases in obesity, dyslipidemia, hypertension, and type 2 diabetes mell
Externí odkaz: https://doaj.org/article/d9f92500df6c4eecb16e7a3bbf12dd82
Zobrazit plný text záznamu
4
Re-administration of nivolumab after immune checkpoint inhibitor-induced cholangitis: the first reported case
Autor: Seita Kataoka, Michihisa Moriguchi, Shinya Okishio, Aya Takahashi, Keiichiro Okuda, Yuya Seko, Atushi Umemura, Kanji Yamaguchi, Aya Miyagawa-Hayashino, Yoshito Itoh
Publikováno v: Clinical Journal of Gastroenterology. 15:467-474
Immune checkpoint inhibitors (ICIs) cause various immune-related adverse events (irAEs). We encountered a patient in whom nivolumab was re-administered effectively and safely treat laryngeal cancer after nivolumab-induced cholangitis. A 60-year-old m
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::195e33b9ebed33d5737add8cde680dfa
https://doi.org/10.1007/s12328-022-01590-z
Zobrazit plný text záznamu
5
Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents
Autor: Yuya Seko, Michihisa Moriguchi, Aya Takahashi, Kanji Yamaguchi, Atsushi Umemura, Keiichiro Okuda, Seita Kataoka, Hidemi Unozawa, Kazufumi Kobayashi, Sadahisa Ogasawara, Rui Sato, Satoshi Tsuchiya, Shunji Watanabe, Naoki Morimoto, Kenji Iwai, Takeshi Aramaki, Naoya Kato, Yoshito Itoh
Publikováno v: Journal of gastroenterology. 57(2)
The aim of this multicenter retrospective study was to evaluate the impact of the eradication of hepatitis C virus (HCV) on the clinical outcomes of patients with hepatocellular carcinoma (HCC) treated with molecular-targeted agents (MTAs).Among 877
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86a7a2031a48867e4b6cb083c0d5150a
https://pubmed.ncbi.nlm.nih.gov/35031857
Zobrazit plný text záznamu
6
Enhanced Antitumor Effect in Liver Cancer by Amino Acid Depletion-Induced Oxidative Stress
Autor: Yu Liu, Kota Yano, Taichiro Nishikawa, Yasuhide Mitsumoto, Yoshihiro Kanbara, Hayato Nakagawa, Atsushi Umemura, Seita Kataoka, Shinya Okishio, Toshihide Shima, Michihisa Moriguchi, Kanji Yamaguchi, Yoshito Itoh, Yuya Seko, Keiichiro Okuda, Takeshi Okanoue, Aya Takahashi, Hiroyoshi Taketani
Publikováno v: Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. HCC cells consume large amounts of glutamine to survive, but can adapt to glutamine depletion in the presence of an exogenous asparagine. L-asparaginase (ASNase) converts
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b30f3747d8ce4ee8b36492f9b62501a
https://pubmed.ncbi.nlm.nih.gov/34796113
Zobrazit plný text záznamu
7
Impact of Insufficient Response with an Increase in Tumor Number in Predicting Transcatheter Arterial Chemoembolization Refractoriness for Hepatocellular Carcinoma
Autor: Yuya Seko, Atsushi Umemura, Seita Kataoka, Naoki Mizuno, Kanji Yamaguchi, Masahito Minami, Taichiro Nishikawa, Yoshito Itoh, Keiichiro Okuda, Michihisa Moriguchi, Masashi Takemura, Koichiroh Yasui, Mitsuhiro Furuta, Tasuku Hara, Hiroyoshi Taketani
Publikováno v: Digestive Diseases. 36:385-394
Aim: In Japan, transcatheter arterial chemoembolization (TACE) refractoriness for hepatocellular carcinoma has been defined as an insufficient therapeutic effect after ≥2 procedures. Insufficient TACE for intrahepatic lesions is defined as the pres
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::343884574ee1a00e85c270f79291111b
https://doi.org/10.1159/000489488
Zobrazit plný text záznamu
8
Honokiol Acts as a Potent Anti-Fibrotic Agent in the Liver through Inhibition of TGF-β1/SMAD Signaling and Autophagy in Hepatic Stellate Cells
Autor: Seita Kataoka, Atsushi Umemura, Keiichiro Okuda, Hiroyoshi Taketani, Yuya Seko, Taichiro Nishikawa, Kanji Yamaguchi, Michihisa Moriguchi, Yoshihiro Kanbara, Jack L. Arbiser, Toshihide Shima, Takeshi Okanoue, Yoshito Itoh
Publikováno v: International Journal of Molecular Sciences
International Journal of Molecular Sciences; Volume 22; Issue 24; Pages: 13354
International Journal of Molecular Sciences, Vol 22, Iss 13354, p 13354 (2021)
Chronic liver injury may result in hepatic fibrosis, which can progress to cirrhosis and eventually liver failure. There are no drugs that are specifically approved for treating hepatic fibrosis. The natural product honokiol (HNK), a bioactive compou
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25ddc5c0bf3440b84f0071420957da9a
https://doi.org/10.3390/ijms222413354
Zobrazit plný text záznamu
10
Honokiol Prevents Non-Alcoholic Steatohepatitis-Induced Liver Cancer via EGFR Degradation through the Glucocorticoid Receptor—MIG6 Axis
Autor: Taichiro Nishikawa, Toshihide Shima, Yuya Seko, Shiori Umemura, Michael Karin, Jack L. Arbiser, Takeshi Okanoue, Yoshito Itoh, Yoshihiro Kanbara, Atsushi Umemura, Seita Kataoka, Keiichiro Okuda, Kanji Yamaguchi, Michihisa Moriguchi, Hiroyoshi Taketani
Publikováno v: Cancers, Vol 13, Iss 1515, p 1515 (2021)
Cancers
Volume 13
Issue 7
Cancers, vol 13, iss 7
Simple Summary Non-alcoholic fatty liver disease (NAFLD) is a major health problem globally linked with the growing prevalence of metabolic syndrome. A subset of patients with NAFLD progress to non-alcoholic steatohepatitis (NASH), which increases th
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4858e5cb861342505aef0c986ab1037c
https://doi.org/10.3390/cancers13071515
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje